about
Cognitive Rehabilitation in Patients with Gliomas and Other Brain Tumors: State of the ArtHypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma.Gonadotropin secreting pituitary adenoma associated with erythrocytosis: case report and literature review.Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment.The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experienceTemozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches.Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches.Assessing response using 99mTc-MIBI early after interstitial chemotherapy with carmustine-loaded polymers in glioblastoma multiforme: preliminary results.5-Aminolevulinic acid fluorescence in high grade glioma surgery: surgical outcome, intraoperative findings, and fluorescence patternsAdvanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.Second-line therapy for refractory renal-cell carcinoma.Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature.Treating patients with metastatic renal carcinoma: an escape from Phase III.An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.Treatment of malignant gliomas in elderly patients: a concise overview of the literature.Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy.Neurocognitive functions and health-related quality of life in glioblastoma patients: a concise review of the literature.Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.Annexin 2A sustains glioblastoma cell dissemination and proliferation.Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy.Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis.Surgery on motor area metastasis.Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results.Open Transcranial Resection of Small (<35 mm) Meningiomas of the Anterior Midline Skull Base in Current Microsurgical Practice.Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma.AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II studyVEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.Urine 2-Hydroxyglutarate in Glioma.Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
P50
Q26738787-4B4CA832-E1CE-4290-8E17-568359E9527EQ30573800-CAC4AD59-B48D-49F6-B234-F428DA27E23BQ30689219-2AD1DBD9-B789-424C-9206-B994FC1A67C8Q30798324-CC51B73F-D8FF-4459-A313-56EFA8A07BC2Q33390672-8FE25932-8738-49D7-826F-BF3D32408C84Q33415187-9929EE95-0DAF-495D-AEE5-40A76E352F4CQ33419582-B86EC356-CB9B-4DCB-A19B-0FE237A57652Q33432135-ADD19C4B-E544-45C5-A232-451EB8104E20Q35584731-6979BFDA-3315-4E2C-B0EC-15E10BA17BEEQ35586677-2C934FC1-5C36-416B-9F7E-DC2418D07772Q37283736-9F32999E-94BD-448B-BED0-50919CCD5209Q37621918-1206CC9C-55FF-4418-B857-7A7BA766BD39Q37700540-47B75924-33FA-4291-8FAA-7447A557A46EQ37720272-94363B72-57EA-4196-A43E-2E8709113929Q37831541-3DA9AEAF-B21E-44F8-BA49-443ACEA59D43Q37938160-9926C240-452C-48D0-AC0A-9DCDE7BC4C26Q37989792-982D7293-A1EF-49E2-848E-1E12C86936F6Q38030592-DE0FD8FB-954A-4AAC-8EED-2AE265890EA7Q38209678-78DC6C83-5C09-42C8-8B9A-94A895B2349CQ38213650-D55006C9-E82E-4FAD-B22C-97310B443D77Q38215192-36B76CD4-951E-4AE0-ABFE-516C24D3E821Q38218549-EAE62DF1-93C2-4603-B416-390B2E7A27ACQ38381406-3A0AF74C-8429-4DDB-9067-90245D501A9BQ38623875-C4484AA2-1843-4935-AFB5-366184493F5BQ38650974-D2D354E3-7320-4F0D-8EA6-3156D923E6DAQ38840667-67556618-AA76-4E7F-90AA-769307312C40Q39128685-01367BFA-7488-49CD-962F-874AE6DB6C4BQ39161484-BF5CBB09-6196-4082-BFCC-08A4311C1D96Q39273311-0A6958F0-B804-45C5-94D3-B1C6812A5ADCQ40307618-8C71D226-C37A-46AF-900E-E74E70D503FDQ40732949-40DE9A60-E48E-4413-9C8B-FD037DE2C1F6Q40913591-40BA443C-1EC9-4BCA-9C9E-621E0BC7DDBDQ40957378-ED6E94B9-53C4-42D7-B281-6685AAF39B93Q40997333-153BEE22-D606-4910-8BB7-6C04F3305EF1Q41139015-2A694FA3-7B34-4442-A099-386D5993161BQ41282384-65E5C6A0-6FD7-455C-AB20-DB8073254BDEQ41547838-53614D17-1AB1-4F82-AAB6-6C280A9973FCQ41714150-7CDDC4E4-7FDE-4BD5-9F0C-2BFCB35DF5B1Q42369973-CF3CF524-FFEC-4EE7-A863-3B4FADF87A7BQ43232546-29E95958-4CA2-4C68-A66D-34CD5B7AAA0C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Lombardi
@ast
Giuseppe Lombardi
@en
Giuseppe Lombardi
@es
Giuseppe Lombardi
@nl
Giuseppe Lombardi
@sl
type
label
Giuseppe Lombardi
@ast
Giuseppe Lombardi
@en
Giuseppe Lombardi
@es
Giuseppe Lombardi
@nl
Giuseppe Lombardi
@sl
prefLabel
Giuseppe Lombardi
@ast
Giuseppe Lombardi
@en
Giuseppe Lombardi
@es
Giuseppe Lombardi
@nl
Giuseppe Lombardi
@sl
P106
P1153
17635174500
P21
P31
P496
0000-0003-1316-2132